-
Novo Nordisk Reports 25% YOY Sales Growth in H1 and Q2 2024, Led by GLP-1 Drugs
•
Novo Nordisk (NYSE: NVO), a Danish pharmaceutical giant specializing in diabetes care, has reported its financial results for the first half and second quarter of 2024. The company achieved a robust 25% year-on-year (YOY) increase in sales, reaching DKK 133,409 million (USD 19,524 billion) in total revenues. This growth was…
-
Pfizer, Astellas, and University of California Sue Qilu Pharma Over Xtandi Patent Infringement
•
Pfizer Inc. (NYSE: PFE), through its subsidiary Medivation, and co-development partner Astellas Pharma Inc. (TYO: 4503), are stepping up their efforts to safeguard the intellectual property of their blockbuster prostate cancer drug, Xtandi (enzalutamide). In a joint legal action with the University of California, the companies have filed a lawsuit…
-
Eli Lilly & Co. Resolves Manufacturing Constraints, Reports 37% YOY Sales Growth in Q2 2024
•
Eli Lilly & Co. (NYSE: LLY), a prominent pharmaceutical company based in the U.S., has reported robust growth in its Q2 2024 financials, highlighting that previous manufacturing capacity constraints affecting its glucagon-like peptide-1 (GLP-1) drugs have been resolved. The company’s global sales growth surged 37% year-on-year (YOY) in constant currency…
-
Viatris Inc. Reports 2% Operational Growth in Q2’24, Driven by Generics and Brands
•
Viatris Inc. has announced its financial results for the second quarter of 2024, highlighting approximately 2% operational growth, reaching net revenues of USD 3.8 billion. Both the generics and brands segments experienced a rise of about 2% each during the quarter. The company also reported new product revenues amounting to…
-
BeiGene’s Q2 2024 Revenues Surge 56% YOY, Highlighted by Strong U.S. Market Performance
•
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has reported its financial results for the second quarter of 2024, with total revenues hitting USD 929 million, representing a robust 56% increase year-on-year (YOY). Product sales accounted for USD 921 million of this total, marking a 66% YOY uptick. Operating losses, according…
-
Betta Pharmaceuticals Reports Strong H1 2024 Revenue Growth and Advances in Drug Development
•
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has reported its financial results for the first half of 2024, showing robust growth. The company recorded revenues of RMB 1.501 billion (USD 209.3 million), marking a 14.22% increase year-on-year (YOY), and a significant surge in net profits to RMB…
-
Organon’s Q2 2024 Revenues Grow 2% YOY, Sets Sights on Fertility Business Rebound in 2025
•
Organon (NYSE: OGN), a U.S.-based pharmaceutical company, has reported its financial results for the second quarter of 2024, with revenues amounting to USD 1.607 billion, marking a modest growth of 2% year-on-year (YOY) in constant currency terms. This performance aligns with market expectations and keeps the company on track to…
-
Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance
•
Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024, showing a 1.7% increase in global net sales to €5.4 billion (USD 5.9 billion) over the three-month period. The company’s performance varied by business segment, with Life Science experiencing a decline of 3.7% year-on-year in…
-
Zai Lab’s Q2 2024 Revenues Soar 47% YOY, Driven by Vyvgart and Zejula Sales
•
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company based in China, has released its financial report for the second quarter of 2024, highlighting recent product milestones and corporate developments. The company reported net revenues of USD 100.1 million for Q2’24, marking a 47% increase year-on-year (YOY) at…
-
Bayer AG’s Q2 2024 Global Group Sales Rise 3.1%, Driven by Pharmaceuticals and Consumer Healthcare
•
Bayer AG (OTCMKTS: BAYZF), a multinational pharmaceutical and life sciences company headquartered in Germany, has reported its financial results for the second quarter of 2024. The company posted a 3.1% year-on-year (YOY) increase in constant currency terms, reaching EUR 11.1 billion (USD 12.12 billion) in global group sales for the…
-
Eisai’s Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling
•
Eisai Co., Ltd (TYO: 4523), a prominent Japanese pharmaceutical company, has released its financial results for the three-month first quarter of the fiscal year 2024, concluded on June 30, 2024. The company reported a slight decline of 4% in total revenues year-on-year (YOY), amounting to JPY 189 billion (USD 1.26…
-
Daiichi Sankyo Reports 24.3% YOY Revenue Growth, Driven by Enhertu and Lixiana
•
Daiichi Sankyo (TYO: 4568), a leading pharmaceutical company in Japan, reported a significant year-on-year (YOY) growth of 24.3%, with revenues reaching JPY 436.18 billion (USD 3.0 billion). This Q1’24 result is notable for being the first to not include revenues from Daiichi Sankyo Espha, the company’s generics unit that was…
-
GE Healthcare’s Q1 2024 Earnings Hit by China, Adjusts Annual Guidance
•
GE Healthcare Technologies Inc. (NASDAQ: GEHC), a leading player in the medical device and life sciences industry, reported its financial results for the first quarter of 2024, with China’s market dynamics being a significant factor in the company’s decision to adjust its annual guidance downward. The company cited the ongoing…
-
Astellas Pharma Reports Robust Q1 FY2024 Results, Highlighting Growth in Core Therapies
•
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the first quarter of the fiscal year 2024, ending June 30, 2024. The company reported a robust performance with a 26.2% increase in global sales, reaching JPY 473,124 million (USD 3.16 billion) compared to the same period last…
-
HutchMed Reports 2024 H1 Financials with Mixed Results Amid Strategic Focus on R&D and Commercial Efficiency
•
China-based HutchMed (NASDAQ: HCM) has released its financial report for the first half of 2024, showing a 41% year-on-year decrease in total revenues to $305.7 million, in constant currency terms. The company’s oncology products segment reported a 64% increase in revenues to $127.8 million, while the oncology/immune business saw a…
-
GSK Reports Q2 2024 Earnings with 13% Growth, Vaccines Unit Sees Mixed Results
•
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has reported its financial results for the second quarter of 2024, showing a robust year-on-year (YOY) growth of 13% in constant currency terms, reaching £7.88 billion ($10.12 billion). The company’s performance was marked by growth across all business units, with the…
-
Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches
•
Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the first quarter of fiscal year 2024, ending June 30, 2024. The company reported a 2.1% increase in global sales year-on-year, reaching ¥1,208 billion ($7.85 billion) at constant exchange rates. Takeda’s Growth and Launch Product portfolio,…
-
Takeda Reports 3.7% YOY Revenue Growth in Q1 2023 Fiscal Year with Priority Products Driving Sales
•
Japan-based multinational Takeda (TYO: 4502) has released its financial report for the fiscal year 2023 Q1 period ended June 30, 2023. The company reported revenues that grew at 3.7% year-on-year (YOY) in constant exchange rate terms to JPY 1.058 trillion (USD 7.44 billion). Takeda CEO Costa Saroukos highlighted that priority…
-
Pfizer Inc. Reports Q2 2024 Earnings with First Positive Growth Since Q4 2022 Peak
•
Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has announced its financial results for the second quarter of 2024, showing a 3% year-on-year (YOY) increase in global revenues in constant currency terms, reaching USD 13.283 billion. This marks the first quarter of positive growth for Pfizer since the peak…
-
Merck’s Q2 2024 Earnings Miss Estimates as China Market Downturn Surprises
•
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has reported its financial results for the second quarter of 2024, with global revenues reaching USD 16.1 billion, marking an 11% increase year-on-year when excluding currency impacts. Despite this growth, the company’s stock price declined by 9.81% as investors reacted to the…
